This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

AspenBio Finds Fault Afar for Failure

CASTLE ROCK, Co. ( TheStreet) -- I must give props to AspenBio Pharma (APPY - Get Report). The company's experimental hospital test for appendicitis went up in flames Monday night, but the excuses dished out by management for the whopping failure and setback to Aspen's AppyScore are destined to become instant classics.

The dog didn't eat AspenBio's Appyscore test results. No, that would be too facile an explanation for 1) why the phase III study failed, and 2) why Aspen is jettisoning plans to seek AppyScore's regulatory approval.

Instead, AspenBio management blamed the poor AppyScore test results -- most notably an alarming number of false positives -- on "transportation shipping conditions" of blood samples from the hospital emergency rooms to a central reading laboratory and the length of time it took those samples to make the trip.

Allow me to translate: What AspenBio's management said Monday is that the dog with AppyScore blood samples in its mouth got on a cross-town bus headed to the central laboratory, but the bus driver got lost and the bus' air-conditioning system broke down so by the time the dog got to the lab, the blood samples were cooked, causing the AppyScore test results to read out a diagnosis of appendicitis when in reality the patients were just fine.

If it weren't for that unfortunate screw up, AppyScore would have been golden. Got that? Understand? Good.

So, AppyScore is dead, just as I warned back in April when AspenBio was trading above $4. The stock closed Monday at 97 cents and was down another 10% in the after-hours session as investors digested the bad news.

Where does AspenBio go from here? Monday night, the company said it would forge ahead with an AppyScore version 2.0 appendicitis test, one that could be administered fully in a hospital emergency room, which theoretically, will eliminate the sample transportation excuses… er, I mean issues… that derailed AppyScore version 1.0.

AspenBio said if all goes well, a pivotal clinical trial of AppyScore 2.0 could start in 2011.

If all goes well… not exactly comforting words from a management team whose only real talent seems to be explaining why stuff doesn't go well.

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on Twitter.
Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
APPY $2.82 -2.10%
AAPL $92.69 -0.59%
FB $119.49 1.40%
GOOG $711.11 1.40%
TSLA $214.84 1.60%


Chart of I:DJI
DOW 17,740.63 +79.92 0.45%
S&P 500 2,057.14 +6.51 0.32%
NASDAQ 4,736.1550 +19.0610 0.40%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs